DISRUPT PAD I

Single-arm, pre-market European study demonstrating the safety and performance of Shockwave IVL as standalone therapy in heavily calcified, fem-pop lesions and followed to 6 months.

DISRUPT PAD I logo
DISRUPT PAD I Logo

Study Leadership

This section contains attributions including profile pictures, titles, descriptions, and Twitter handles.

  • Andrew Holden , MD
    Co-Principal Investigator Auckland City Hospital, New Zealand
  • Thomas Zeller, MD
    Co-Principal Investigator Universitäts-Herzzentrum Bad Krozingen, Germany

Statistics Callout

This section presents key statistical information with numbers and descriptions.

  • 35
    Patients followed out to six months
  • 98
    %
    Severely calcified lesions by PARC
  • 80
     mm
    Average calcified length

Compelling Safety & Performance in Severely Calcified Lesions* 

Statistics Callout

This section presents key statistical information with numbers and descriptions.

  • 100
    %
    Procedural success
  • 0
    %
    Perforations, embolization, slow/no reflow, abrupt closure
  • 23
    %
    Final residual stenosis with an acute gain of 2.9 mm
  • 82.1
    %
    Patency
  • 100
    %
    Freedom from clinically-driven target lesion revascularization

*Core Lab and CEC adjudicated. Results are at 6 months for patency and TLR. 

Check out the full DISRUPT PAD I study results on JACC